In order to better guide the safe and rational use of drugs in clinical practice, our company, in accordance with the requirements of the "Special Provisions on the Registration Management of Traditional Chinese Medicine" announced by the National Medical Products Administration (No. 20, 2023), has proactively conducted post-marketing research on the safety information of Qizao Granules, revised the contents of "Adverse Reactions", "Contraindications" and "Precautions" in the instructions and la

In order to better guide clinical safe and rational drug use, our company, in accordance with the requirements of the announcement (No. 20 of 2023) issued by the National Medical Products Administration regarding the "Special Provisions for Drug Registration Management of Traditional Chinese Medicine", has actively carried out a listing study on the safety information items of Daqi Li San. We have revised the contents of the instructions and labels regarding "Adverse Reactions", "Contraindicatio